Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study...

por Gupta, Neeraj, Labotka, Richard, Liu, Guohui, Hui, Ai-Min, Venkatakrishnan, Karthik
Publicado 2016

Model‐Based Meta‐Analysis for Multiple Myeloma: A Quantitative Drug‐Independent Framework for Efficient Decisions in Oncology Drug Development

por Teng, Zhaoyang, Gupta, Neeraj, Hua, Zhaowei, Liu, Guohui, Samnotra, Vivek, Venkatakrishnan, Karthik, Labotka, Richard
Publicado 2017

Clinical Pharmacology of Ixazomib: The First Oral Proteasome Inhibitor

por Gupta, Neeraj, Hanley, Michael J., Xia, Cindy, Labotka, Richard, Harvey, R. Donald, Venkatakrishnan, Karthik
Publicado 2018

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE‐MM1 study in multiple myeloma patients

por Srimani, Jaydeep K., Diderichsen, Paul M., Hanley, Michael J., Venkatakrishnan, Karthik, Labotka, Richard, Gupta, Neeraj
Publicado 2022

Impact of ixazomib‐lenalidomide‐dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging‐markets subgroup of the TOURMALINE‐MM1 trial...

por Spencer, Andrew, Samoilova, Olga, Chng, Wee‐Joo, Labotka, Richard, Li, Cong, Wu, Kwang‐Wei, Saxena, Nakul, Yan, Xu, Lee, Jae Hoon, Beksac, Meral
Publicado 2022

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

por Gupta, Neeraj, Hanley, Michael J., Venkatakrishnan, Karthik, Perez, Raymond, Norris, Robin E., Nemunaitis, John, Yang, Huyuan, Qian, Mark G., Falchook, Gerald, Labotka, Richard, Fu, Siqing
Publicado 2016

Model‐Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor

por Gupta, Neeraj, Hanley, Michael J., Diderichsen, Paul M., Yang, Huyuan, Ke, Alice, Teng, Zhaoyang, Labotka, Richard, Berg, Deborah, Patel, Chirag, Liu, Guohui, van de Velde, Helgi, Venkatakrishnan, Karthik
Publicado 2018

Deepening responses associated with improved progression-free survival with ixazomib versus placebo as posttransplant maintenance in multiple myeloma

por Goldschmidt, Hartmut, Dimopoulos, Meletios A., Rajkumar, S. Vincent, Weisel, Katja C., Moreau, Philippe, Chng, Wee-Joo, Mikala, Gábor, Cavo, Michele, Ramasamy, Karthik, Suryanarayan, Kaveri, Teng, Zhaoyang, Labotka, Richard, Mateos, Maria Victoria
Publicado 2020

A pooled analysis of outcomes according to cytogenetic abnormalities in patients receiving ixazomib- vs placebo-based therapy for multiple myeloma

por Chng, Wee-Joo, Lonial, Sagar, Morgan, Gareth J., Iida, Shinsuke, Moreau, Philippe, Kumar, Shaji K., Twumasi-Ankrah, Philip, Villarreal, Miguel, Dash, Ajeeta B., Vorog, Alexander, Zhang, Xiaoquan, Suryanarayan, Kaveri, Labotka, Richard, Dimopoulos, Meletios A., Rajkumar, S. Vincent
Publicado 2023

Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma

por Kaiser, Martin, Beksaç, Meral, Gulbrandsen, Nina, Schjesvold, Fredrik, Hájek, Roman, Moreau, Philippe, de Arriba de la Fuente, Felipe, Mateos, María-Victoria, West, Sharon, Spencer, Andrew, Rajkumar, S. Vincent, Suryanarayan, Kaveri, Czorniak, Michael, Li, Cong, Teng, Zhaoyang, Labotka, Richard, Dimopoulos, Meletios A.
Publicado 2020

Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

por Dimopoulos, Meletios A., Špička, Ivan, Quach, Hang, Oriol, Albert, Hájek, Roman, Garg, Mamta, Beksac, Meral, Bringhen, Sara, Katodritou, Eirini, Chng, Wee-Joo, Leleu, Xavier, Iida, Shinsuke, Mateos, María-Victoria, Morgan, Gareth, Vorog, Alexander, Labotka, Richard, Wang, Bingxia, Palumbo, Antonio, Lonial, Sagar
Publicado 2020

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

por Paiva, Bruno, Manrique, Irene, Dimopoulos, Meletios A., Gay, Francesca, Min, Chang-Ki, Zweegman, Sonja, Špička, Ivan, Teipel, Raphael, Mateos, María-Victoria, Giuliani, Nicola, Cavo, Michele, Hopkins, Christine Rojas, Fu, Weijun, Suryanarayan, Kaveri, Vorog, Alexander, Li, Cong, Wang, Bingxia, Estevam, Jose, Labotka, Richard, Dash, Ajeeta B.
Publicado 2023

Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial

por Dimopoulos, Meletios A., Schjesvold, Fredrik, Doronin, Vadim, Vinogradova, Olga, Quach, Hang, Leleu, Xavier, Montes, Yolanda Gonzalez, Ramasamy, Karthik, Pompa, Alessandra, Levin, Mark-David, Lee, Cindy, Mellqvist, Ulf Henrik, Fenk, Roland, Demarquette, Hélène, Sati, Hamdi, Vorog, Alexander, Labotka, Richard, Du, Jichang, Darif, Mohamed, Kumar, Shaji
Publicado 2022

Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE‐MM2 trial

por Richardson, Paul G., Facon, Thierry, Venner, Christopher P., Bahlis, Nizar J., Offner, Fritz, White, Darrell, Karlin, Lionel, Benboubker, Lotfi, Voog, Eric, Yoon, Sung‐Soo, Suzuki, Kenshi, Shibayama, Hirohiko, Zhang, Xiaoquan, Villarreal, Miguel, Twumasi‐Ankrah, Philip, Labotka, Richard, Rifkin, Robert M., Lonial, Sagar, Kumar, Shaji K., Rajkumar, S. Vincent, Moreau, Philippe
Publicado 2023

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

por Dimopoulos, Meletios A., Jakubowiak, Andrzej J., McCarthy, Philip L., Orlowski, Robert Z., Attal, Michel, Bladé, Joan, Goldschmidt, Hartmut, Weisel, Katja C., Ramasamy, Karthik, Zweegman, Sonja, Spencer, Andrew, Huang, Jeffrey S. Y., Lu, Jin, Sunami, Kazutaka, Iida, Shinsuke, Chng, Wee-Joo, Holstein, Sarah A., Rocci, Alberto, Skacel, Tomas, Labotka, Richard, Palumbo, Antonio, Anderson, Kenneth C.
Publicado 2020